Fact CheckerSign in

NCT02717650Completed

The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis.

Development; Feasibility/Safety and Validation of the Alfred Step Test Exercise Protocol (A-STEP) Developed for Adults With Cystic Fibrosis:

Source: ClinicalTrials.gov · Last updated 11 Aug 2025

Brief summary (registry, in English)

Exercise testing has become clinically important in the management and ongoing evaluation of patients with Cystic Fibrosis (CF) with higher rates of exercise tolerance and participation previously linked to lower mortality risk (1). Lower exercise capacity generally correlates with more severe lung disease (2,3) and landmark studies suggest that low exercise capacity as measured by peak oxygen capacity (VO2peak) and rate of decline in lung function (FEV1) are strong predictors of mortality (1,4). However not all studies have found pulmonary function tests (PFTs) to be reliable predictors of maximal exercise capacity (5), especially in relatively well preserved lung function (6,7). The wide distribution in physical capacity between fit individuals and end stage disease adds to complexity of assessment. Independent factors of age, genetics, habitual exercise, nutritional status and musculoskeletal conditions are all known to influence physical capacity in patients with CF (8,9). Maximal exercise testing places additional stress on cardiovascular, respiratory and peripheral systems providing more information around multiple influences on disease progression including degree of limitation in these major systems (10,11) and is useful for assessment of exercise desaturation, more common (but not always present) in advanced lung disease (5,12). With prediction of exercise performance and functional capacity from PFTs unreliable and the understanding that health status correlates better with exercise tolerance there has been an increase in maximal exercise testing for patient management (13). Many international centers now regard exercise testing as highly important with many assessing maximal exercise capacity annually to monitor disease progression, identify physical status and drive changes in medical, physiotherapy or nutritional management (14,15). The main vision is to develop a standardized incremental step test protocol suitable for adults with Cystic Fibrosis (CF), all ages, levels of fitness and disease state that is in line with current exercise testing recommendations (15). To develop a more useful field test to assess exercise tolerance and a more "user friendly" test than the currently available laboratory exercise test to allow for early detection of decline in physical function in the day-to-day clinical setting. To date no studies have been published in adults with CF where an incremental exercise step test has been investigated to assess exercise tolerance or determine maximum oxygen uptake (VO2max).

Status (registry)
Completed
Study type
Interventional
Enrollment
7 (actual)
First submitted
10 Mar 2016
Start date
Aug 2016
Primary completion date
Mar 2024
Lead sponsor
The Alfred
NCT number
NCT02717650

What you commit to

  • Study type: Interventional
  • Participants enrolled: 7
  • From Aug 2016 to the primary completion date, Mar 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • INCLUSION
  • Confirmed Diagnosis of CF (by genotype or positive sweat test)
  • Aged 18yrs and older
  • FEV1 ≥20% (Forced expiration in 1 sec)
  • Stable baseline state. (Stable baseline state is defined as: clinically stable respiratory status, for at least 30 days, characterized by the absence of hospitalization and no changes in maintenance therapy during this period (Yankaskas et al 2004)).
    • EXCLUSION
  • Febrile
  • Haemoptysis
  • Uncontrolled asthma
  • Pneumothorax
  • Cardiac issues
  • Unreliable readings on pulse oximetry
  • Pulmonary hypertension
  • Unstable CF related diabetes (CFRD)
  • Vascular issues
  • Renal disease
  • Pregnancy
  • Body mass index (BMI) \<18.0
  • Significant musculoskeletal issues
  • Unable to safely follow instructions
    • (ATS/ACCP 2003; Hebestreit 2015)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Alfred Hospital
Coordinator of this site? Confirm its status
MelbourneAustraliaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.